Literature DB >> 7681152

Different binding epitopes on the NK1 receptor for substance P and non-peptide antagonist.

U Gether1, T E Johansen, R M Snider, J A Lowe, S Nakanishi, T W Schwartz.   

Abstract

Non-peptide ligands for peptide receptors have been discovered in several systems through file screening programs, but the mechanism of action for these candidate drugs is obscure as they do not chemically resemble the native peptides. The compound CP 96345 is a high-affinity, non-peptide antagonist of the substance P (NK1) receptor, which is important in pain perception and neurogenic inflammation. Here we identify epitopes on the NK1 receptor responsible for the specific binding of CP 96345 by systematic exchange of corresponding segments between the NK1 receptor and the homologous NK3 (neurokinin B) receptor, which does not bind the non-peptide ligand. Non-conserved residues, in two epitopes around the top of transmembrane segment V and in one epitope at the top of transmembrane segment VI, are essential for the specific action of CP 96345 on the NK1 receptor, but are surprisingly not important for the binding of the natural peptide ligand, substance P. Susceptibility to the non-peptide antagonists can be conveyed to the previously unresponsive NK3 receptor by mutational transfer of this discontinuous epitope from the NK1 receptor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7681152     DOI: 10.1038/362345a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  24 in total

1.  Mutational analysis and molecular modeling of the nonapeptide hormone binding domains of the [Arg8]vasotocin receptor.

Authors:  H Hausmann; A Richters; H J Kreienkamp; W Meyerhof; H Mattes; K Lederis; H Zwiers; D Richter
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

Review 2.  Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.

Authors:  Inga Herpfer; Klaus Lieb
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 3.  Mode matches and their locations in the hydrophobic free energy sequences of peptide ligands and their receptor eigenfunctions.

Authors:  A J Mandell; K A Selz; M F Shlesinger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

4.  Molecular recognition of peptide and non-peptide ligands by the extracellular domains of neurohypophysial hormone receptors.

Authors:  J Howl; M Wheatley
Journal:  Biochem J       Date:  1996-07-15       Impact factor: 3.857

Review 5.  Somatostatin.

Authors:  T Reisine
Journal:  Cell Mol Neurobiol       Date:  1995-12       Impact factor: 5.046

Review 6.  Modes of peptide binding in G protein-coupled receptors.

Authors:  M Berthold; T Bartfai
Journal:  Neurochem Res       Date:  1997-08       Impact factor: 3.996

7.  Two nonpeptide tachykinin antagonists act through epitopes on corresponding segments of the NK1 and NK2 receptors.

Authors:  U Gether; Y Yokota; X Emonds-Alt; J C Brelière; J A Lowe; R M Snider; S Nakanishi; T W Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

8.  Effects of the tachykinin NK1 receptor antagonist, RP 67580, on central cardiovascular and behavioural effects of substance P, neurokinin A and neurokinin B.

Authors:  J Culman; B Wiegand; H Spitznagel; S Klee; T Unger
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

9.  Pharmacological characterisation of neurokinin receptors mediating anion secretion in rat descending colon mucosa.

Authors:  H M Cox; I R Tough; K Grayson; S Yarrow
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-08       Impact factor: 3.000

10.  Construction of a novel bifunctional biogenic amine receptor by two point mutations of the H2-histamine receptor.

Authors:  J DelValle; I Gantz; L Wang; Y J Guo; G Munzert; T Tashiro; Y Konda; T Yamada
Journal:  Mol Med       Date:  1995-03       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.